| Somc Medical Care Foundation, Inc. | |
|
1805 27th St Portsmouth OH 45662-2640 | |
| (740) 356-8681 | |
| (740) 356-1256 |
| Full Name | Somc Medical Care Foundation, Inc. |
|---|---|
| Speciality | Family Medicine |
| Location | 1805 27th St, Portsmouth, Ohio |
| Authorized Official Name and Position | Rebecca L Fite (ADMINISTRATIVE DIRECTOR) |
| Authorized Official Contact | 7403568008 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Somc Medical Care Foundation, Inc. 1735 27th St Waller Building, Suite B06 Portsmouth OH 45662-2677 Ph: (740) 356-8008 | Somc Medical Care Foundation, Inc. 1805 27th St Portsmouth OH 45662-2640 Ph: (740) 356-8681 |
| NPI Number | 1457467227 |
|---|---|
| Provider Enumeration Date | 08/22/2006 |
| Last Update Date | 01/30/2024 |
| Certification Date | 01/30/2024 |
| Medicare PECOS PAC ID | 9436061645 |
|---|---|
| Medicare Enrollment ID | O20031125000203 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457467227 | NPI | - | NPPES |
| 0916512 | Medicaid | OH | |
| 65921835 | Medicaid | KY |
| Provider Name | Robert E Newman |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1154491249 PECOS PAC ID: 5890607006 Enrollment ID: I20031106000097 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Matthew G Hutchins |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1114926813 PECOS PAC ID: 0648183715 Enrollment ID: I20031106000295 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | James Otworth |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1487615209 PECOS PAC ID: 2466359344 Enrollment ID: I20031218000026 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Daniel P Marck |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1750466082 PECOS PAC ID: 4789582172 Enrollment ID: I20031223000035 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Scott Logan |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1154321867 PECOS PAC ID: 1355249319 Enrollment ID: I20040106000024 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Karen S Hergenreder |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1265484083 PECOS PAC ID: 2668372517 Enrollment ID: I20040108001219 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Diana C Hyden |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1093813529 PECOS PAC ID: 7416858147 Enrollment ID: I20040116000016 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Rayann S Huntsman |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1629039441 PECOS PAC ID: 3274436159 Enrollment ID: I20040128001033 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Barbara M Mastriana |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1639146525 PECOS PAC ID: 3173419587 Enrollment ID: I20040224000256 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Nathan H Kander |
|---|---|
| Provider Type | Practitioner - Interventional Cardiology |
| Provider Identifiers | NPI Number: 1073518940 PECOS PAC ID: 6204738057 Enrollment ID: I20040303000551 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Vernon D Reynolds |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1174600852 PECOS PAC ID: 6406744655 Enrollment ID: I20040309000436 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Rena Zimmerman |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1851350318 PECOS PAC ID: 9537058417 Enrollment ID: I20040311000183 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | G Garth Grant |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1114910486 PECOS PAC ID: 2466351234 Enrollment ID: I20040326000248 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kathryn Opal Lusenhop |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1487611216 PECOS PAC ID: 2668465386 Enrollment ID: I20040407000538 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Joy A Bennett |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1285649970 PECOS PAC ID: 9830090281 Enrollment ID: I20040503001626 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | James J Sardo |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1992750145 PECOS PAC ID: 4880676675 Enrollment ID: I20040607000033 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Louis Salib |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1023003480 PECOS PAC ID: 1153304423 Enrollment ID: I20040608001225 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Cynthia G Hamm |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1487760237 PECOS PAC ID: 8022092410 Enrollment ID: I20040615000030 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Lori A Guinn |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1730266214 PECOS PAC ID: 9931172152 Enrollment ID: I20040817000066 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kimberly Sue Umhoefer |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1225140007 PECOS PAC ID: 7618943341 Enrollment ID: I20040907000016 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jim R Armstrong |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1972505899 PECOS PAC ID: 4688642572 Enrollment ID: I20040920000051 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Peter K Bauer |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1548261761 PECOS PAC ID: 3476521717 Enrollment ID: I20040923000642 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Bryan H Fuller |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1104898592 PECOS PAC ID: 2264400233 Enrollment ID: I20041014000158 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Steven William Mccornack |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1669459772 PECOS PAC ID: 6204885718 Enrollment ID: I20050121000257 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Toni E Miller |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1912083007 PECOS PAC ID: 7113978057 Enrollment ID: I20050208000571 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Gregory Karasik |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1144299884 PECOS PAC ID: 1153373634 Enrollment ID: I20050211000848 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Roland E Benton |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1891774675 PECOS PAC ID: 5890789192 Enrollment ID: I20050504000330 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Nadeem N Malik |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1306822275 PECOS PAC ID: 8224071675 Enrollment ID: I20050607000122 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Mary Ann T Gardner |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1861422206 PECOS PAC ID: 3870536857 Enrollment ID: I20050610000023 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Michael E Martin |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1629170600 PECOS PAC ID: 2466496690 Enrollment ID: I20050617000381 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Nanci L Burton |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1780623314 PECOS PAC ID: 8123091956 Enrollment ID: I20050822000019 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Tiffany L Harris |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1639176753 PECOS PAC ID: 4981635760 Enrollment ID: I20050823000006 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Vincent H Randaisi |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1114915279 PECOS PAC ID: 6608807003 Enrollment ID: I20050829001089 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Deidre Redd |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1306995865 PECOS PAC ID: 1658397658 Enrollment ID: I20051019000555 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Debra Skerlec-caylor |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1639168917 PECOS PAC ID: 9739105693 Enrollment ID: I20051019001132 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Philip E Willis |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1457331670 PECOS PAC ID: 7012812985 Enrollment ID: I20051108000677 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Raymond Gathiuni |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1609927763 PECOS PAC ID: 0547288417 Enrollment ID: I20051109000469 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Joseph R Leith |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1598719890 PECOS PAC ID: 6305856279 Enrollment ID: I20060424000162 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Mary C Vaughn-greathouse |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1942240643 PECOS PAC ID: 7719980952 Enrollment ID: I20060809000083 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Tammam H Abdul-aziz |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1457343816 PECOS PAC ID: 3173526001 Enrollment ID: I20060816000054 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Augusto C Juguilon |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1043269434 PECOS PAC ID: 0244235240 Enrollment ID: I20060926000374 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Charanjit Singh Bahniwal |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1225028020 PECOS PAC ID: 1658376397 Enrollment ID: I20061002000186 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | James T Wolfe |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1174502934 PECOS PAC ID: 5991700668 Enrollment ID: I20061002000528 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Timothy C Mcglone |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1861443004 PECOS PAC ID: 9436156593 Enrollment ID: I20061102000216 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Arthur J Ramey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1932299161 PECOS PAC ID: 9739187246 Enrollment ID: I20061116000543 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | David W Tesar |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1205913746 PECOS PAC ID: 9133127566 Enrollment ID: I20061120000336 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Robin Lee Franklin |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1659444511 PECOS PAC ID: 8325047228 Enrollment ID: I20061204000010 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | William Titman |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1285726745 PECOS PAC ID: 2567463433 Enrollment ID: I20070119000005 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Christy L Martin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255409108 PECOS PAC ID: 3678574126 Enrollment ID: I20070125000319 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Stella Ling |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1871695700 PECOS PAC ID: 0941269997 Enrollment ID: I20070129000319 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Darren Chad Adams |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1770549024 PECOS PAC ID: 0244232130 Enrollment ID: I20070206000274 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Erika H Poehm |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1669448551 PECOS PAC ID: 6305881939 Enrollment ID: I20070215000303 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kevin Francis Forsthoefel |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1982605010 PECOS PAC ID: 1850333931 Enrollment ID: I20070312000377 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kimberly A Queener |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1750308110 PECOS PAC ID: 3678671534 Enrollment ID: I20070531000366 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Nancy Jeanne Smith |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1154343747 PECOS PAC ID: 2769403807 Enrollment ID: I20070613000824 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | David E Riley |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1568481976 PECOS PAC ID: 2769581735 Enrollment ID: I20070618000030 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Vincent M Scarpinato |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1275614026 PECOS PAC ID: 9830105907 Enrollment ID: I20070621000408 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Matthew S Schwamburger |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1457552119 PECOS PAC ID: 9133210727 Enrollment ID: I20070810000701 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Blessing Otoabasi Godwin |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1538245618 PECOS PAC ID: 7719080456 Enrollment ID: I20070813000168 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Darby W Wehrley |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1306935226 PECOS PAC ID: 8921190034 Enrollment ID: I20070822000049 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Christine C Christensen |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1871595405 PECOS PAC ID: 3870546823 Enrollment ID: I20070906000120 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Justin Greenlee |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1467655647 PECOS PAC ID: 1658464466 Enrollment ID: I20070911000157 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Boonlieng Wongchaowart |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1255431748 PECOS PAC ID: 3971698168 Enrollment ID: I20071003000260 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jitendra Patel |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1346224995 PECOS PAC ID: 7810999778 Enrollment ID: I20071203000427 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Nan Nelson |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1396816625 PECOS PAC ID: 3577653708 Enrollment ID: I20071212000196 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kevin T Harris |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1841474517 PECOS PAC ID: 6608957287 Enrollment ID: I20080122000272 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Angela Y Rackley |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1619178621 PECOS PAC ID: 3375626898 Enrollment ID: I20080207000051 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Mark T Wagner |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1346373446 PECOS PAC ID: 7416031034 Enrollment ID: I20080221000036 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | John C Lee |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1730175019 PECOS PAC ID: 9537065859 Enrollment ID: I20080228000237 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Nnamdi Azie |
|---|---|
| Provider Type | Practitioner - Cardiac Surgery |
| Provider Identifiers | NPI Number: 1851366892 PECOS PAC ID: 2264483049 Enrollment ID: I20080307000108 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Eugene Vitvitsky |
|---|---|
| Provider Type | Practitioner - Cardiac Surgery |
| Provider Identifiers | NPI Number: 1578507299 PECOS PAC ID: 1153212063 Enrollment ID: I20080428000666 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jay E Risheh |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1386690485 PECOS PAC ID: 3870663529 Enrollment ID: I20080606000249 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Luis F Benitez Lopez |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1154368892 PECOS PAC ID: 0244300903 Enrollment ID: I20080606000378 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Mohamed Fouad Soumakieh |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1487696720 PECOS PAC ID: 0345285326 Enrollment ID: I20080808000028 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Travis L Chabo |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1124178942 PECOS PAC ID: 2163528910 Enrollment ID: I20080813000046 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kurt Palazzo |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1649298258 PECOS PAC ID: 4284700915 Enrollment ID: I20080904000164 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Meilani Hasmin Mapa |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1063600872 PECOS PAC ID: 3678655149 Enrollment ID: I20081008000058 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Elie M Saab |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1447218169 PECOS PAC ID: 0547163123 Enrollment ID: I20081123000002 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Rockford James Meadows |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1346454154 PECOS PAC ID: 6800957762 Enrollment ID: I20090220000035 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Loretta A Settonni |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1023011137 PECOS PAC ID: 7214824762 Enrollment ID: I20090318000143 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kristie J Thacker |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1780820597 PECOS PAC ID: 0143387639 Enrollment ID: I20090327000343 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Yan Chen |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1659455160 PECOS PAC ID: 7911006721 Enrollment ID: I20090406000217 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kenneth R Greer |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1336265602 PECOS PAC ID: 5597740548 Enrollment ID: I20090422000093 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Matthew Onyekelu |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1316189764 PECOS PAC ID: 9335232560 Enrollment ID: I20090504000007 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Amy E Spencer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275770315 PECOS PAC ID: 0941358840 Enrollment ID: I20090504000191 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Shay L Price |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1013113836 PECOS PAC ID: 0345321741 Enrollment ID: I20090601000543 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Masood Siddiqui |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1902034663 PECOS PAC ID: 8022161371 Enrollment ID: I20090807000482 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Roger Matthew Phillips |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1477724235 PECOS PAC ID: 4880749423 Enrollment ID: I20090902000460 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Muhammad Taimoor Gill |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1033323381 PECOS PAC ID: 4082714563 Enrollment ID: I20090911000220 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jeffrey E Parker |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1942299565 PECOS PAC ID: 6002908977 Enrollment ID: I20090918000038 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Marion R Hochstetler |
|---|---|
| Provider Type | Practitioner - Thoracic Surgery |
| Provider Identifiers | NPI Number: 1336346808 PECOS PAC ID: 7315093127 Enrollment ID: I20090921000224 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Phillip D Roberts |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1871742338 PECOS PAC ID: 9234276726 Enrollment ID: I20091103000194 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Angela M Shupert |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1821043449 PECOS PAC ID: 3577597137 Enrollment ID: I20091217000369 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | John Shupert |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1932148160 PECOS PAC ID: 0941195622 Enrollment ID: I20091229000476 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Anil Jagetia |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1023019486 PECOS PAC ID: 6204908809 Enrollment ID: I20100119000189 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Gretchen Rhea Horner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962667691 PECOS PAC ID: 3577622521 Enrollment ID: I20100415000351 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Chandreshkumar S Shah |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1437154234 PECOS PAC ID: 1052398633 Enrollment ID: I20100602000044 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Angel R Ali |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093042087 PECOS PAC ID: 3577693035 Enrollment ID: I20100609000542 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Mark T Tawil |
|---|---|
| Provider Type | Practitioner - Cardiac Surgery |
| Provider Identifiers | NPI Number: 1285620179 PECOS PAC ID: 4486786738 Enrollment ID: I20100722000006 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Edward Chen |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1104868272 PECOS PAC ID: 9638202419 Enrollment ID: I20100730000100 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | George William Shahade |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1588777825 PECOS PAC ID: 3870581887 Enrollment ID: I20100813000278 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Richard Randall Jacobs |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1447457171 PECOS PAC ID: 6305738550 Enrollment ID: I20100913001178 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Duane Marchyn |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1104846906 PECOS PAC ID: 5890728554 Enrollment ID: I20101026000085 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Brennon E Giles |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194034553 PECOS PAC ID: 4688868599 Enrollment ID: I20101104000039 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Meshelle A Lynch |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1144520198 PECOS PAC ID: 3779779558 Enrollment ID: I20101118000874 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Yinong Liu |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1457357758 PECOS PAC ID: 4981662178 Enrollment ID: I20110225000401 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kaitlyn H Jakubec |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1184920712 PECOS PAC ID: 8921289604 Enrollment ID: I20110301000492 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jared Carson Bentley |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1114238805 PECOS PAC ID: 5698957124 Enrollment ID: I20110307000667 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Bobbie C Sutton |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1093807083 PECOS PAC ID: 7810186343 Enrollment ID: I20110311000317 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Justin D Nolen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1366743569 PECOS PAC ID: 8022291301 Enrollment ID: I20110323001003 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Nathan E Rider |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1669782413 PECOS PAC ID: 1456535368 Enrollment ID: I20110418000213 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Margaret A Guest |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1700830148 PECOS PAC ID: 6002869526 Enrollment ID: I20110606000495 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Cynthia Bayer |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1407818164 PECOS PAC ID: 6204809296 Enrollment ID: I20110613000129 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Nathan D Bennington |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1972777589 PECOS PAC ID: 2668641820 Enrollment ID: I20110805000062 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jenifer R Combs |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1932493871 PECOS PAC ID: 1557532181 Enrollment ID: I20110912000453 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jessica N Powell |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1386893832 PECOS PAC ID: 1355512633 Enrollment ID: I20110916000189 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kuldeep Vaghela |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1255544037 PECOS PAC ID: 5092857367 Enrollment ID: I20111209000435 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Ahmed Arshad |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1154461531 PECOS PAC ID: 1759579634 Enrollment ID: I20111212000353 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Marsha S Smith |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1528003548 PECOS PAC ID: 1355312927 Enrollment ID: I20111220000283 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Franchaska D Grimes |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1629354188 PECOS PAC ID: 4284892134 Enrollment ID: I20120223000047 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kari L Ward |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285917096 PECOS PAC ID: 8527227867 Enrollment ID: I20120306001003 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Ron J Miller |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1962601229 PECOS PAC ID: 7416117700 Enrollment ID: I20120323000197 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Steven L Woolley |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1831189935 PECOS PAC ID: 4082895321 Enrollment ID: I20120718000152 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Johnny R Bernard |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1972510493 PECOS PAC ID: 6204005010 Enrollment ID: I20120718000476 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Robert B Roach |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1295725398 PECOS PAC ID: 7416140082 Enrollment ID: I20120801000270 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Cara D Taylor |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1588910723 PECOS PAC ID: 5799932000 Enrollment ID: I20120821000910 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Catherine A Price |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1144576364 PECOS PAC ID: 4183871957 Enrollment ID: I20120829000853 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Molly R Stine |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1497004709 PECOS PAC ID: 7012165947 Enrollment ID: I20120918000327 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Cheryl K Wilson |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1558610964 PECOS PAC ID: 7618125386 Enrollment ID: I20120921000439 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jesse P Houghton |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1457529125 PECOS PAC ID: 8123105707 Enrollment ID: I20121011000792 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Emma Khan |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1386861508 PECOS PAC ID: 3375669393 Enrollment ID: I20130110000632 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Ellen Stolyar |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1497989016 PECOS PAC ID: 6901945294 Enrollment ID: I20130423000366 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Adam Wilson |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1033167028 PECOS PAC ID: 0648418541 Enrollment ID: I20130605000409 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Joseph D Augustin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053759456 PECOS PAC ID: 3072753045 Enrollment ID: I20130716000365 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | David Joseph Gooden |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1679725105 PECOS PAC ID: 0042450926 Enrollment ID: I20130717000804 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Chad D Lore |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407296536 PECOS PAC ID: 3072755685 Enrollment ID: I20130812000299 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Tabitha J Stefanov |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1629410048 PECOS PAC ID: 7911149166 Enrollment ID: I20130816000841 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Farryn R Bussa |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457792152 PECOS PAC ID: 1052554425 Enrollment ID: I20130904000463 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Amy L Kilburn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1225461643 PECOS PAC ID: 3577707546 Enrollment ID: I20130912000296 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Amy Lynn Huff |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1770898538 PECOS PAC ID: 6507059888 Enrollment ID: I20130920000535 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Paul D Rase |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245665090 PECOS PAC ID: 4486551124 Enrollment ID: I20131017000987 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Cindy D Hammond |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871832485 PECOS PAC ID: 0648409276 Enrollment ID: I20140131000524 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Julie Lynne Carr |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508990540 PECOS PAC ID: 5799915732 Enrollment ID: I20140313000529 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | David K Byers |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1114022712 PECOS PAC ID: 5496938037 Enrollment ID: I20140319001333 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Muhammad Rahman |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1487748406 PECOS PAC ID: 6709781289 Enrollment ID: I20140424001956 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Ludivina T Warren |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376968453 PECOS PAC ID: 9032342027 Enrollment ID: I20140428001141 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Michael T Smith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902223423 PECOS PAC ID: 5698908499 Enrollment ID: I20140501001535 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Amy J Flinders |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124469416 PECOS PAC ID: 2668695503 Enrollment ID: I20140522001462 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Young-mi Pruden |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1477783371 PECOS PAC ID: 6901029313 Enrollment ID: I20140603000477 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Patrick Mcdonough |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1558697599 PECOS PAC ID: 2365680212 Enrollment ID: I20140604002377 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Bakkiam Subbiah |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1033197629 PECOS PAC ID: 8325038482 Enrollment ID: I20140708001014 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Ryan F Sandlin |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1114246063 PECOS PAC ID: 4284851916 Enrollment ID: I20140804001504 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Ted J Stidham |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1134428402 PECOS PAC ID: 0648497289 Enrollment ID: I20140805003130 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jessica S Suber |
|---|---|
| Provider Type | Practitioner - Plastic And Reconstructive Surgery |
| Provider Identifiers | NPI Number: 1033379375 PECOS PAC ID: 7911124730 Enrollment ID: I20140818002325 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Tyler Evans |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1538494513 PECOS PAC ID: 8921247206 Enrollment ID: I20140820002685 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Ilham Ahmad Smidi |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1053729509 PECOS PAC ID: 1355560293 Enrollment ID: I20140908002743 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Tarun R Nagrani |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1427203652 PECOS PAC ID: 4688893357 Enrollment ID: I20140910002160 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Mikell N Rase |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1487944542 PECOS PAC ID: 9133348303 Enrollment ID: I20140920000361 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Javaid A Malik |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1114985520 PECOS PAC ID: 0244120459 Enrollment ID: I20140930001768 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Tiffany A Kiley |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1386053544 PECOS PAC ID: 2961623632 Enrollment ID: I20141021002899 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Ryan D Nichols |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1215378872 PECOS PAC ID: 1557582129 Enrollment ID: I20141023001273 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Keri A Kuhn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1558779173 PECOS PAC ID: 8527289867 Enrollment ID: I20141029002476 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kemmely H Hochstetler |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1992993638 PECOS PAC ID: 9133299209 Enrollment ID: I20141030002089 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jason Trotter |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1679715551 PECOS PAC ID: 8820276124 Enrollment ID: I20141117000014 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Angela D Gilliland |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235388968 PECOS PAC ID: 7315169786 Enrollment ID: I20141119001993 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kristal S Dailey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629271424 PECOS PAC ID: 5294057170 Enrollment ID: I20141203001832 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | John R Radford |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1508884503 PECOS PAC ID: 0840512539 Enrollment ID: I20141208002423 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Samuel Albert Morgos |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1144364076 PECOS PAC ID: 5294764817 Enrollment ID: I20141215002067 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jason Swords |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518364546 PECOS PAC ID: 7911220157 Enrollment ID: I20141219001533 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Brandon Grant |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1730584525 PECOS PAC ID: 4981927514 Enrollment ID: I20150106001214 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Valerie Decamp |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1922413764 PECOS PAC ID: 8426373010 Enrollment ID: I20150202000369 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Cynthia D Watson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1326441916 PECOS PAC ID: 0042535197 Enrollment ID: I20150211002053 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Annette R Smith |
|---|---|
| Provider Type | Practitioner - Critical Care (intensivists) |
| Provider Identifiers | NPI Number: 1336171297 PECOS PAC ID: 1951393040 Enrollment ID: I20150218000682 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Dana N Beck |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174913479 PECOS PAC ID: 8022334069 Enrollment ID: I20150310000790 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Udaya Shreesha |
|---|---|
| Provider Type | Practitioner - Critical Care (intensivists) |
| Provider Identifiers | NPI Number: 1093762213 PECOS PAC ID: 6204866163 Enrollment ID: I20150326002086 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Robert David Lane |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114944683 PECOS PAC ID: 7810990827 Enrollment ID: I20150423002027 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Irina A Scott |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1245586866 PECOS PAC ID: 5496903767 Enrollment ID: I20150424001381 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Vickie L Thomas |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376630384 PECOS PAC ID: 2264533017 Enrollment ID: I20150528000792 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Fred J Kahan |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1780616623 PECOS PAC ID: 3779477948 Enrollment ID: I20150530000078 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Diana E Young |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265837249 PECOS PAC ID: 9537480082 Enrollment ID: I20150609001233 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kayla R Harris |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689054314 PECOS PAC ID: 9931411790 Enrollment ID: I20150708000198 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Mohit Datta |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1720217102 PECOS PAC ID: 2961657176 Enrollment ID: I20150720003098 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Erika Isaacs |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1457733750 PECOS PAC ID: 3577877091 Enrollment ID: I20150728005656 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Brandy Jo Branham |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043697972 PECOS PAC ID: 7113231382 Enrollment ID: I20150731015742 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Allison Hamilton Bentley |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1902199268 PECOS PAC ID: 4587802012 Enrollment ID: I20150811003771 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Manaf Zaizafoun |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1174787972 PECOS PAC ID: 2365516481 Enrollment ID: I20150812008390 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jason Ross |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1932584869 PECOS PAC ID: 6709191158 Enrollment ID: I20150814013023 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Adham S Jammoul |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1316247364 PECOS PAC ID: 3971818204 Enrollment ID: I20150817000784 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Cadee A Schumacher |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063842490 PECOS PAC ID: 5799091898 Enrollment ID: I20150903002880 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Diana Maria Hursh |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1578539771 PECOS PAC ID: 2365439791 Enrollment ID: I20150908001598 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kristie L Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962895524 PECOS PAC ID: 1759609191 Enrollment ID: I20150916001944 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Melissa M Beck |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1366811937 PECOS PAC ID: 8224347380 Enrollment ID: I20151013000204 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Rebecca R Kalb |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265803878 PECOS PAC ID: 9931418274 Enrollment ID: I20151027002530 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kimberly M Williams |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1174996003 PECOS PAC ID: 3375843469 Enrollment ID: I20151120001806 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kayla L Ross |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1366814428 PECOS PAC ID: 8628379047 Enrollment ID: I20151209000261 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Audrey Hull |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1679959126 PECOS PAC ID: 6608177100 Enrollment ID: I20151228001531 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Ashley E Wilkett |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497120539 PECOS PAC ID: 4688976095 Enrollment ID: I20151231000649 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | James E Tate |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1760474977 PECOS PAC ID: 7810942869 Enrollment ID: I20160104002471 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Eric C Rost |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1407839103 PECOS PAC ID: 3779562632 Enrollment ID: I20160113002244 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Troy A Prather |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1467441022 PECOS PAC ID: 7719912294 Enrollment ID: I20160203002704 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Stehanie J Cummings |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285094664 PECOS PAC ID: 9739486739 Enrollment ID: I20160317002175 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Patrick K Amartey |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1346211190 PECOS PAC ID: 7416941042 Enrollment ID: I20160411001798 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Michael L Purdy |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1033573910 PECOS PAC ID: 3971802844 Enrollment ID: I20160427000704 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Nicholas Toppins |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144681487 PECOS PAC ID: 4385933639 Enrollment ID: I20160510001731 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | James R Pacholka |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1255395646 PECOS PAC ID: 5294890190 Enrollment ID: I20160518002271 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | John Collins |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1003830399 PECOS PAC ID: 4789640681 Enrollment ID: I20160525000603 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jeremiah T Martin |
|---|---|
| Provider Type | Practitioner - Thoracic Surgery |
| Provider Identifiers | NPI Number: 1235310707 PECOS PAC ID: 6002072394 Enrollment ID: I20160526001808 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Arrika J Mains |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1194081109 PECOS PAC ID: 1456641117 Enrollment ID: I20160608001401 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Sherry L Young |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801236815 PECOS PAC ID: 6901048586 Enrollment ID: I20160706001040 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Ziad Alsokary |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1972772184 PECOS PAC ID: 7810076403 Enrollment ID: I20160823003224 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Mario Christianto |
|---|---|
| Provider Type | Practitioner - Critical Care (intensivists) |
| Provider Identifiers | NPI Number: 1457611337 PECOS PAC ID: 5294968160 Enrollment ID: I20160915002721 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Dustin Johnson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1033439492 PECOS PAC ID: 7012104763 Enrollment ID: I20160928000467 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | April Greene |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801342548 PECOS PAC ID: 1254629199 Enrollment ID: I20161010002030 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Alexander J Barrow |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1982051983 PECOS PAC ID: 8527346444 Enrollment ID: I20161027002581 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | J Humberto H Hernandez |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1457432635 PECOS PAC ID: 5395633051 Enrollment ID: I20161101000467 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Novera Inam |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1215975354 PECOS PAC ID: 1557431996 Enrollment ID: I20161116002786 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Sree Latha Krishna Jadapalle |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1578820452 PECOS PAC ID: 3870873581 Enrollment ID: I20161214001390 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kristin Nickles |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588115828 PECOS PAC ID: 6800177254 Enrollment ID: I20161227001391 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jay M Hamze |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1356321442 PECOS PAC ID: 2163466095 Enrollment ID: I20161230001339 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | George A Stephen |
|---|---|
| Provider Type | Practitioner - Sleep Medicine |
| Provider Identifiers | NPI Number: 1518064997 PECOS PAC ID: 7214991124 Enrollment ID: I20170112002959 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Gurkiran Gill |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1194967216 PECOS PAC ID: 9931425915 Enrollment ID: I20170209001602 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Daniel L Milam |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1265553655 PECOS PAC ID: 1951485077 Enrollment ID: I20170301000599 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Steven William Guyton |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1154344307 PECOS PAC ID: 4587767819 Enrollment ID: I20170313001669 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Lloyd David Hubler |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1215986419 PECOS PAC ID: 3173414570 Enrollment ID: I20170313002350 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Holly C Hannon |
|---|---|
| Provider Type | Practitioner - Sleep Medicine |
| Provider Identifiers | NPI Number: 1801990197 PECOS PAC ID: 3072610765 Enrollment ID: I20170404001279 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Eric Steckler |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1972503514 PECOS PAC ID: 5698933794 Enrollment ID: I20170503001445 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Alton Dunlap |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1154723153 PECOS PAC ID: 9335464346 Enrollment ID: I20170628001821 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Michael Markow |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1194091892 PECOS PAC ID: 1052607983 Enrollment ID: I20170710001372 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Joseph W Herrmann |
|---|---|
| Provider Type | Practitioner - Vascular Surgery |
| Provider Identifiers | NPI Number: 1740504885 PECOS PAC ID: 9931416906 Enrollment ID: I20170725001787 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Linda Lester |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1548783889 PECOS PAC ID: 7618248964 Enrollment ID: I20170803003217 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Caylee L Hopkins |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629508981 PECOS PAC ID: 7911278197 Enrollment ID: I20170807000992 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Sarica Lillie |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1326568528 PECOS PAC ID: 3072884956 Enrollment ID: I20170810003694 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Andrew Dittenhofer |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1174811764 PECOS PAC ID: 4688946106 Enrollment ID: I20170817004037 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Christopher G Belton |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1710920590 PECOS PAC ID: 7618974056 Enrollment ID: I20170914003323 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Nanda K Methuku |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1952596405 PECOS PAC ID: 7810062916 Enrollment ID: I20171004001185 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Amanda J Williams |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639692759 PECOS PAC ID: 1254606916 Enrollment ID: I20171005000606 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Andrew Shaheen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871002030 PECOS PAC ID: 9739454968 Enrollment ID: I20171013001099 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | David B Huang |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1154325652 PECOS PAC ID: 4183519093 Enrollment ID: I20180103002114 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Andrew M Sopchak |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1164494969 PECOS PAC ID: 5991994634 Enrollment ID: I20180205001058 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Larika D Moore |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093213613 PECOS PAC ID: 5395005250 Enrollment ID: I20180214001442 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Natalie R Spears |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831588573 PECOS PAC ID: 8628367299 Enrollment ID: I20180216001606 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Thomas S Haas |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1821177973 PECOS PAC ID: 8820074222 Enrollment ID: I20180228002361 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jade Kirkpatrick |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861901829 PECOS PAC ID: 7315208246 Enrollment ID: I20180309001051 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Justin Robert Stegman |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1467962886 PECOS PAC ID: 8426310046 Enrollment ID: I20180320000990 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | D 'wan Carpenter |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1447518386 PECOS PAC ID: 7911210927 Enrollment ID: I20180326000374 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Ikbal Alkhafaji |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1851418164 PECOS PAC ID: 9335402296 Enrollment ID: I20180406001450 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | James Andrew Eads |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1659434710 PECOS PAC ID: 6103873963 Enrollment ID: I20180604001497 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Clara E Smith |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1922599711 PECOS PAC ID: 1557616877 Enrollment ID: I20180608001750 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Briana D Otworth |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265932008 PECOS PAC ID: 6103173463 Enrollment ID: I20180718002801 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Ray A Ervin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1356851893 PECOS PAC ID: 0446519003 Enrollment ID: I20180827001938 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Denise M Duffy |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194219949 PECOS PAC ID: 8921358409 Enrollment ID: I20180904001888 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Elaine Jones |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1912965864 PECOS PAC ID: 4789622358 Enrollment ID: I20180924002064 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | James Milton Jones |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1700974177 PECOS PAC ID: 2466415872 Enrollment ID: I20180927001788 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Yousef K Kaid |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1194012112 PECOS PAC ID: 8224258744 Enrollment ID: I20181026000389 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Gary L Eddy |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1508825324 PECOS PAC ID: 1951384544 Enrollment ID: I20190109003297 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Laura F Sova |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780917898 PECOS PAC ID: 0547415473 Enrollment ID: I20190114002224 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Joseph A Wapenski |
|---|---|
| Provider Type | Practitioner - Neurosurgery |
| Provider Identifiers | NPI Number: 1487654281 PECOS PAC ID: 1153229463 Enrollment ID: I20190214001619 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Sanjiv M Kaul |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1588659247 PECOS PAC ID: 0345383139 Enrollment ID: I20190221001897 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Brittany Bolton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114491461 PECOS PAC ID: 7517206782 Enrollment ID: I20190306000089 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Traci Swingler |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1548725773 PECOS PAC ID: 7517207350 Enrollment ID: I20190314001075 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Sara E Reed |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417413279 PECOS PAC ID: 2769722537 Enrollment ID: I20190314002104 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Philip A Witek |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1639584402 PECOS PAC ID: 8426311127 Enrollment ID: I20190318000728 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Cheryl A Dahlstroem |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1619480027 PECOS PAC ID: 9436418928 Enrollment ID: I20190320003344 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Adam Evans |
|---|---|
| Provider Type | Practitioner - Interventional Radiology |
| Provider Identifiers | NPI Number: 1053748822 PECOS PAC ID: 0446573943 Enrollment ID: I20190520002612 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Sona K Shah |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1083667695 PECOS PAC ID: 6507878477 Enrollment ID: I20190522001051 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Tara R. Applegate |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447611652 PECOS PAC ID: 8820397391 Enrollment ID: I20190524002345 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jami Michelle Lyon |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1083057178 PECOS PAC ID: 8325398704 Enrollment ID: I20190529002580 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Wilson Christian |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1932528296 PECOS PAC ID: 8022241157 Enrollment ID: I20190606000626 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Misty L Hawk |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720543457 PECOS PAC ID: 1658604541 Enrollment ID: I20190607001596 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Yara D Nazzal |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1477845584 PECOS PAC ID: 3173832995 Enrollment ID: I20190717003018 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | David T Newman |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1114589413 PECOS PAC ID: 9335476878 Enrollment ID: I20190807001112 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Dolores Contreras-urby |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1356390744 PECOS PAC ID: 3577695022 Enrollment ID: I20190824000479 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Matthew Watson |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1720320658 PECOS PAC ID: 5890929020 Enrollment ID: I20190826003399 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Elizabeth A Bentley |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1740421130 PECOS PAC ID: 1355629536 Enrollment ID: I20190827002629 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Stacia Boyer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528613346 PECOS PAC ID: 6800124918 Enrollment ID: I20190828001486 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | John G Rutter |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1891709549 PECOS PAC ID: 9638171515 Enrollment ID: I20190905002700 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Adam Bray |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245888734 PECOS PAC ID: 5496085631 Enrollment ID: I20191001001961 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Natosha L Staggs |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629535190 PECOS PAC ID: 7911238258 Enrollment ID: I20191017000515 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Cindi Bradley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1205313574 PECOS PAC ID: 1052218799 Enrollment ID: I20191023002280 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jackie Pierson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447808936 PECOS PAC ID: 4486986973 Enrollment ID: I20191104000099 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Wahid Rashidzada |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1346416021 PECOS PAC ID: 0749334738 Enrollment ID: I20191212001617 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Stella A Ugboma |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1073574919 PECOS PAC ID: 6204735921 Enrollment ID: I20191218002236 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Brea D Boggs-cline |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437793692 PECOS PAC ID: 2961836754 Enrollment ID: I20200103000545 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Richard Jackson |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1932427218 PECOS PAC ID: 4880810282 Enrollment ID: I20200115002974 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Christopher C Wiler |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1699248575 PECOS PAC ID: 6608113634 Enrollment ID: I20200118000051 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Caleb Davis |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1528416427 PECOS PAC ID: 7416382148 Enrollment ID: I20200127001187 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Cynthia Napier |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1023454907 PECOS PAC ID: 6800038449 Enrollment ID: I20200221001054 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Matthew R Sloan |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1861674087 PECOS PAC ID: 7810074135 Enrollment ID: I20200422002921 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Daniel C Sufficool |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1083098669 PECOS PAC ID: 1456774629 Enrollment ID: I20200706003041 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Charles R Roberts |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1386262251 PECOS PAC ID: 1355766916 Enrollment ID: I20200730001587 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Vanessa L Wanjeri |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1033564521 PECOS PAC ID: 1456777374 Enrollment ID: I20200821001284 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Deanna J Potter |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083225031 PECOS PAC ID: 5698192227 Enrollment ID: I20200827003147 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Alisha M Wyscarver |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1578094413 PECOS PAC ID: 6002187861 Enrollment ID: I20201013003091 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Holly L Travis |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871195305 PECOS PAC ID: 6305258625 Enrollment ID: I20201210000875 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Courtney Elaine Moore |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497351993 PECOS PAC ID: 5294148417 Enrollment ID: I20210107002446 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kendall L Stewart |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1215014550 PECOS PAC ID: 8921902503 Enrollment ID: I20210301002737 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Shad T Ruby |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1700476900 PECOS PAC ID: 0244254175 Enrollment ID: I20210304001294 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kayla M Tackett |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013502798 PECOS PAC ID: 3072920545 Enrollment ID: I20210329002550 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Derek A Lawhorn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952932642 PECOS PAC ID: 2567871684 Enrollment ID: I20210430002096 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Luke T Porginski |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417547506 PECOS PAC ID: 5799194692 Enrollment ID: I20210505002083 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Scott Edward Kauffman |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1437146842 PECOS PAC ID: 0345272241 Enrollment ID: I20210507000826 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kelsey Louise Potter |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1619597010 PECOS PAC ID: 1456750702 Enrollment ID: I20210519000820 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | William C Ferguson |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1841866415 PECOS PAC ID: 1951702422 Enrollment ID: I20210622003082 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Francis Joseph Moorhead |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1255445664 PECOS PAC ID: 3173411659 Enrollment ID: I20210624003543 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Phu S Le |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1073046371 PECOS PAC ID: 0244577625 Enrollment ID: I20210714002625 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jenny R White |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1063866606 PECOS PAC ID: 0941606107 Enrollment ID: I20210914000548 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Timothy J Young |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1932722659 PECOS PAC ID: 6103249362 Enrollment ID: I20211112000539 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Samantha Lore |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851057350 PECOS PAC ID: 6002206331 Enrollment ID: I20211201000481 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Rebecca Jo Adams |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1821518655 PECOS PAC ID: 6002230422 Enrollment ID: I20220125001989 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Pamela P Clegg |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1922091859 PECOS PAC ID: 4789787490 Enrollment ID: I20220218000012 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Ashley L Risner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831840990 PECOS PAC ID: 6709270515 Enrollment ID: I20220221001777 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Madison L Wiseman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477206522 PECOS PAC ID: 7315331121 Enrollment ID: I20220221001919 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Khanh T Vu |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1538425947 PECOS PAC ID: 3678797875 Enrollment ID: I20220309001628 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Tatiana Vasylievna Barsukova |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1093974057 PECOS PAC ID: 5496935710 Enrollment ID: I20220310000627 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Carole Hunt |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1770160194 PECOS PAC ID: 5799181475 Enrollment ID: I20220318000104 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Denise Francois |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1720048598 PECOS PAC ID: 2466501036 Enrollment ID: I20220504002426 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Blake Barnes |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1912674151 PECOS PAC ID: 1355720806 Enrollment ID: I20220614001509 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Lawrence Ingber |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1841326782 PECOS PAC ID: 3779682687 Enrollment ID: I20220620001033 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Paul Crutchfield |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1710982103 PECOS PAC ID: 3577460088 Enrollment ID: I20220621001811 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | April Dawn Pemberton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1326337494 PECOS PAC ID: 1557764156 Enrollment ID: I20220630000256 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Charles Stephen Woolums |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1699772665 PECOS PAC ID: 4183638323 Enrollment ID: I20220721001117 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jason B Crabtree |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063173771 PECOS PAC ID: 0547641615 Enrollment ID: I20220722002182 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Bahig Shehata |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1932167624 PECOS PAC ID: 7113051830 Enrollment ID: I20220816003034 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Joseph L Sailors |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1861461311 PECOS PAC ID: 5597828848 Enrollment ID: I20220830000517 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Lorine M Lagatta |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1588722201 PECOS PAC ID: 4284987942 Enrollment ID: I20220908000647 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Paul Richard Ramey |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1598320129 PECOS PAC ID: 9436485778 Enrollment ID: I20221006000341 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jeffrey July |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1558004994 PECOS PAC ID: 2466828538 Enrollment ID: I20221013002931 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Tori Howell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1700508769 PECOS PAC ID: 3274909155 Enrollment ID: I20221018000888 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jordyn N Thiel |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1568997211 PECOS PAC ID: 8123495470 Enrollment ID: I20221031000914 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Jasmine P Thompson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437874278 PECOS PAC ID: 8820465636 Enrollment ID: I20221108002779 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | John M Sheldon |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1467415646 PECOS PAC ID: 8527017904 Enrollment ID: I20221108003592 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Andrew O'halloran |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1740713775 PECOS PAC ID: 4082982137 Enrollment ID: I20221123000319 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Courtney Marie Harris |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1649995994 PECOS PAC ID: 8224406111 Enrollment ID: I20221128000676 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Ashley N Crace-speas |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902544414 PECOS PAC ID: 9335518133 Enrollment ID: I20221219001139 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Harlan I Rumjahn |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1063570232 PECOS PAC ID: 7911377007 Enrollment ID: I20230106000330 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Bradley J Craft |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417669391 PECOS PAC ID: 0648641084 Enrollment ID: I20230124000555 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Essam Kazmouz |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1851551162 PECOS PAC ID: 1456411099 Enrollment ID: I20230131002537 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Umera Paracha |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1558717850 PECOS PAC ID: 2163810680 Enrollment ID: I20230209001611 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Brian J Robertson-dick |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1033452453 PECOS PAC ID: 9133419021 Enrollment ID: I20230217000570 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Matthew A Penix |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487352076 PECOS PAC ID: 5496128563 Enrollment ID: I20230310001905 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Lene R Oglesby |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1518075647 PECOS PAC ID: 8022119312 Enrollment ID: I20230313001776 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kenneth G Fortress |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1487650180 PECOS PAC ID: 3173705753 Enrollment ID: I20230405002515 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Anirudh Gupta |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1306259668 PECOS PAC ID: 8628484946 Enrollment ID: I20230503003112 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Heidi J Eizman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1225799091 PECOS PAC ID: 9436516689 Enrollment ID: I20230605000673 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Larry Zhao |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1700012689 PECOS PAC ID: 7416262621 Enrollment ID: I20230620000457 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Elizabeth Mathis |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1003206046 PECOS PAC ID: 5395062251 Enrollment ID: I20230711001883 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Timothy Jacob Burton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053919779 PECOS PAC ID: 5799196465 Enrollment ID: I20230731000840 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Hans H Kim |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1750885687 PECOS PAC ID: 1254681448 Enrollment ID: I20230811002245 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kriti Kalra Sehgal |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1184065336 PECOS PAC ID: 4880822204 Enrollment ID: I20230919000992 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Amy L Mason |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497367593 PECOS PAC ID: 5193139384 Enrollment ID: I20230922000915 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Yaoxian Ding |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1427033943 PECOS PAC ID: 5698706489 Enrollment ID: I20231005000298 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Kimberly R Kelley Harper |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1265413272 PECOS PAC ID: 8921900366 Enrollment ID: I20231016003200 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Katherine D Redmond |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1669038956 PECOS PAC ID: 9436504958 Enrollment ID: I20231018001083 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Laura Molina |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1215577309 PECOS PAC ID: 1759717515 Enrollment ID: I20240126001959 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | James Harris |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598161184 PECOS PAC ID: 5496070773 Enrollment ID: I20240215003928 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
| Provider Name | Nevine Hanna |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1205170982 PECOS PAC ID: 9537471495 Enrollment ID: I20240301002695 |
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
News Archive
Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy.
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has achieved certification to the internationally recognized standard ISO 9001:2015 for its quality management system.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.
› Verified 7 days ago
Spectrumcare, Llc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1112 Gallia St, Portsmouth, OH 45662 Phone: 740-981-3176 | |
Port45 Recovery Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1907 11th St, Portsmouth, OH 45662 Phone: 740-529-7356 | |
Scioto Family And Behavioral Medicine Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4502 Gallia St, Portsmouth, OH 45662 Phone: 740-529-7020 Fax: 740-529-7085 | |
Path Integrated Healthcare Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 902 Gallia St, Portsmouth, OH 45662 Phone: 740-529-2125 Fax: 740-529-2126 | |
Shawnee Mental Health Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 901 Washington St, Portsmouth, OH 45662 Phone: 740-354-7702 Fax: 740-353-1662 | |
Piece By Piece Learning Center Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 411 Harding Ave, Portsmouth, OH 45662 Phone: 740-250-4077 | |
Southern Ohio Medical Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1805 27th St, Portsmouth, OH 45662 Phone: 740-353-1105 |